# ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)

> **NCT02194231** · PHASE2 · COMPLETED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 145 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **DRUG:** Trabectedin

## Key facts

- **NCT ID:** NCT02194231
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2019-12-12
- **Final completion:** 2019-12-12
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2020-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02194231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02194231, "ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02194231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*